Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)73
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers41
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis38
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study36
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies31
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function26
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients26
The inflammatory regulation of TRPA1 expression in human A549 lung epithelial cells24
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d21
Editorial Board20
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens20
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets19
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential19
Editorial Board19
Editorial Board19
Comparing the outcomes of intrapleural fibrinolytic and DNase therapy versus intrapleural fibrinolytic or DNase therapy: A systematic review and meta-analysis18
Characteristics of patients with severe asthma who experienced treatment failure with omalizumab18
0.10735988616943